-
November 6, 2019
R&D Pipeline as of November 2019 -
November 6, 2019
The Second Quarter of FY2019 (April 2019 - September 2019) -
September 26, 2019
Annual Report 2019 -
July 30, 2019
The First Quarter of FY2019 (April 2019 - June 2019) -
May 8, 2019
Annual of FY2018 (April 2018 - March 2019)
-
December 9, 2019
Positive results from uterine fibroids phase-III PRIMROSE 2 trial of Linzagolix -
November 26, 2019
Positive topline data from pivotal phase-III ADVOCATE trial demonstrating avacopan's superiority over standard of care in ANCA vasculitis -
November 26, 2019
Launch of "Darbepoetin Alfa BS Injection [JCR]" for the Treatment of Renal Anemia -
September 20, 2019
Kissei Initiates Phase III Clinical Trial for Fostamatinib in Japanese Patients with Chronic Idiopathic Thrombocytopenic Purpura -
September 20, 2019
JCR Receives Marketing Approval in Japan for Darbepoetin Alfa BS Injection JCR, a Long-Acting Erythropoiesis-Stimulating Agent
